title: New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA.
authors.affiliation: Duke University Medical Center and Medical Research Service, Durham VA Medical Center, Durham, North Carolina.
authors.forename: David S
authors.initials: DS
authors.lastname: Pisetsky
authors.affiliation: The Ohio State University, Wexner Medical Center, Columbus.
authors.forename: Brad H
authors.initials: BH
authors.lastname: Rovin
authors.affiliation: RILITE Foundation, Charlottesville, Virginia.
authors.forename: Peter E
authors.initials: PE
authors.lastname: Lipsky
mesh_terms: D000974:Antibodies, Antinuclear / Q000097:blood* / Q000276:immunology; D018501:Antirheumatic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D002986:Clinical Trials as Topic; D004247:DNA / Q000276:immunology; D004608:Eligibility Determination; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000097:blood* / Q000188:drug therapy; D015203:Reproducibility of Results; D012219:Rheumatology
chemical_list: D000974:Antibodies, Antinuclear; D018501:Antirheumatic Agents; D015415:Biomarkers; D004247:DNA